ID | 58740 |
フルテキストURL | |
著者 |
Tomita, Yoshihiko
Department of Urology, Niigata University Graduate School of Medical and Dental Sciences
Naito, Sei
Department of Urology, Yamagata University Faculty of Medicine
Sassa, Naoto
Department of Urology, Nagoya University Graduate School of Medicine
Takahashi, Atsushi
Department of Urology, Hakodate Goryoukaku Hospital
Kondo, Tsunenori
Department of Urology, Tokyo Women's Medical University Medical Center East
Koie, Takuya
Department of Urology, Hirosaki University Graduate School of Medicine
Obara, Wataru
Department of Urology, Iwate Medical University
Kobayashi, Yasuyuki
Department of Urology, Okayama University Graduate School of Medicine
ORCID
Kaken ID
Teishima, Jun
Department of Urology, Graduate School of Biomedical Health Science, Hiroshima University
Takahashi, Masayuki
Department of Urology, Tokushima University Graduate School of Biomedical Sciences
Matsuyama, Hideyasu
Department of Urology, Yamaguchi University Graduate School of Medicine
Ueda, Takeshi
Department of Urology, Chiba Cancer Center
Yamaguchi, Kenya
Department of Urology, Nihon University School of Medicine
Kishida, Takeshi
Department of Urology, Kanagawa Cancer Center
Shiroki, Ryoichi
Department of Urology, Fujita Health University School of Medicine
Saika, Takashi
Department of Urology, Ehime University
Shinohara, Nobuo
Department of Urology, Hokkaido University Graduate School of Medicine
Oya, Mototsugu
Department of Urology, Keio University School of Medicine
Kanayama, Hiro-omi
Department of Urology, Tokushima University Graduate School of Biomedical Sciences
|
抄録 | Purpose: The present study compared the efficacy of sunitinib and sorafenib as first-line treatment of metastatic clear cell renal cell carcinoma (mCC-RCC) with favorable or intermediate Memorial Sloan Kettering Cancer Center (MSKCC) risk.
Patients and methods: Treatment-naive patients with mCC-RCC were randomized to receive open-label sunitinib followed by sorafenib (SU/SO) or sorafenib followed by sunitinib (SO/SU). The primary endpoint was first-line progression-free survival (PFS). The secondary endpoints were total PFS and overall survival (OS). Results: Of the 124 patients enrolled at 39 institutions from February 2010 to July 2012, 120 were evaluated. The median first-line PFS duration was 8.7 and 7.0 months in the SU/SO and SO/SU groups, respectively (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.42-1.08). The total PFS and OS were not significantly different between the SU/SO and SO/SU groups (27.8 and 22.6 months; HR, 0.73; 95% CI, 0.428-1.246; and 38.4 and 30.9 months; HR, 0.934; 95% CI, 0.588-1.485, respectively). The subgroup analysis revealed that the total PFS with SU/SO was superior to the total PFS with SO/SU in the patients with favorable MSKCC risk and those with < 5 metastatic sites). SO/SU was superior to SU/SO for patients without previous nephrectomy. Conclusions: No statistically significant differences were found in first-line PFS, total PFS, or OS between the 2 treatment arms (ClinicalTrials.gov identifier, NCT01481870). |
キーワード | PFS
RCT
Renal cell carcinoma
SO/SU
SU/SO.
|
発行日 | 2020-03-06
|
出版物タイトル |
Clinical Genitourinary Cancer
|
出版者 | Elsevier
|
ISSN | 15587673
|
NCID | AA12109476
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2020 The Authors. Published by Elsevier Inc.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
関連URL | isVersionOf https://doi.org/10.1016/j.clgc.2020.01.001
|
ライセンス | http://creativecommons.org/licenses/by-nc-nd/4.0/
|
オープンアクセス(出版社) |
OA
|
オープンアーカイブ(出版社) |
非OpenArchive
|